- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07944690
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HLX49 (Anti-HER2 Biparatopic and Bispecific ADC) in Participants With Advanced/Metastatic Solid Tumors
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of HLX49 in patients with advanced/metastatic solid tumors.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
In the phase Ia of this study, an accelerated titration and 3 + 3 dose escalation method will be adopted, and the patients will be administered with HLX49 at different doses via intravenous infusion. The DLT observation period lasts for 3 weeks after the first administration of HLX49.
In phase Ib of this study, the Safety Review Committee will recommend dose groups for expansion based on the safety, efficacy, and PK data of the dose escalation phase. The dose expansion part will enroll patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) who have previously failed first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. Patients will be randomized to receive different doses of HLX49 or the active comparator (trastuzumab deruxtecan, T-DXd).
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Lin Shen
- Numéro de téléphone: +86 10 88196561
- E-mail: doctorshenlin@sina.cn
Lieux d'étude
-
-
-
Sunshine Coast, Australie
- Sunshine Coast University Hospital
-
Contact:
- Hong Shue
- Numéro de téléphone: +61 7 5479 0000
- E-mail: hong.shue@schoc.com.au
-
-
-
-
-
Beijing, Chine
- Beijing Cancer Hospital
-
Contact:
- Lin Shen
- Numéro de téléphone: +86 10 88196561
- E-mail: doctorshenlin@sina.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Willing and able to provide written informed consent and comply with the study protocol.
- Age: 18 to 75 years for Phase Ia; ≥ 18 years for Phase Ib. 3.Tumor Type & Prior Treatment: Phase Ia: Histologically or cytologically confirmed advanced or metastatic solid tumors that are refractory to standard treatment, or for which no standard treatment is available.
Phase Ib (GC/GEJC cohort): Histologically or cytologically confirmed advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) that has progressed during or after exactly one prior line of systemic therapy containing trastuzumab (or a biosimilar).
4.Confirmed HER2-positive status (Phase Ia: IHC 3+ or 2+; Phase Ib: IHC 3+ or IHC 2+/ISH+).
5.ECOG performance status score of 0 or 1. 6.At least one measurable lesion. 7.Life expectancy of more than 3 months. 8.Adequate washout period from prior treatments (e.g., at least 28 days for chemotherapy, radiotherapy, immunotherapy, or major surgery; at least 14 days for targeted therapy or hormone therapy) and recovery of previous treatment-related adverse events.
9.Must provide a tumor tissue sample for biomarker evaluation. 10.Adequate organ and bone marrow function as defined by protocol-specified laboratory tests.
11.Male and female participants with reproductive potential must agree to use highly effective contraception methods; female participants of childbearing potential must have a negative pregnancy test.
Exclusion Criteria:
- History of other malignant tumors within 2 years prior to the first dose (with exceptions for cured early-stage cancers like cervical carcinoma in situ or non-melanoma skin cancer).
- History of severe eye diseases (e.g., severe keratopathy or moderate to severe dry eye).
- History of or current interstitial lung disease (ILD) or non-infectious pneumonitis requiring systemic steroids.
- Severe allergic reactions to monoclonal antibodies or allergy to any component of the investigational product.
- Active systemic infections requiring intravenous antibiotics.
- Requirement for treatment with systemic corticosteroids or other immunosuppressive medications within 2 weeks prior to the first dose.
- Clinically significant cardiovascular diseases, including but not limited to: severe/unstable angina, myocardial infarction within 6 months, symptomatic congestive heart failure, LVEF <50%, poorly controlled hypertension, or clinically significant prolonged QTc interval.
- Symptomatic or uncontrolled brain or meningeal metastases, or spinal cord compression.
- Active or suspected autoimmune diseases (exceptions apply for well-controlled type 1 diabetes and autoimmune hypothyroidism on replacement therapy).
- Unhealed major wounds or anticipation of major surgery during the study.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
- Use of strong CYP3A inhibitors or inducers within 2 weeks prior to the first dose.
- Active tuberculosis.
- Known history of immunodeficiency, including HIV, or history of solid organ transplantation.
- Active Hepatitis B (HBV) or Hepatitis C (HCV) infection (exceptions apply for stable/controlled HBV or HCV meeting specific viral load criteria).
- Pregnant or breastfeeding females.
- Subjects who are assessed as unsuitable for participating in this clinical study due to any clinical or laboratory abnormalities or other reasons by the investigator.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Ia (Dose Escalation)
Patients with advanced/metastatic solid tumors, who are refractory to standard treatment or for which no standard treatment is available. |
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first). |
|
Expérimental: Ib HLX49 Dose 1 (Dose Expansion)
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. |
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first). |
|
Expérimental: Ib HLX49 Dose 2 (Dose Expansion)
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. |
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first). |
|
Expérimental: Ib HLX49 Dose 3 (Dose Expansion)
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. |
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first). |
|
Comparateur actif: Ib Trastuzumab deruxtecan (Dose Expansion)
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. |
Patients with good tolerability and well controlled disease will receive Trastuzumab deruxtecan via intravenous infusion once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first). |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The Dose-Limiting Toxicity (DLT) of HLX49 within 21 days after the first Administration
Délai: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
|
DLT refers to the AEs that are determined to be related to the investigational product by the investigator, whose severity will affect the escalation of dose level. In this study, the DLT observation period lasts for 3 weeks (21 days) after the first administration of HLX49. |
From first dose to the end of Cycle 1 (each cycle is 3 weeks).
|
|
The maximum tolerated dose (MTD) of HLX49
Délai: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
|
The highest dose level, at which DLT is observed in no more than one of 6 evaluable patients, is defined as MTD of HLX49. |
From first dose to the end of Cycle 1 (each cycle is 3 weeks).
|
|
RP2D
Délai: Approximately up to 24 months.
|
The recommended phase 2 dose (RP2D) of HLX49 in participants with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma. |
Approximately up to 24 months.
|
|
Objective response rate (ORR) assessed by IRRC
Délai: Approximately up to 24 months.
|
Percentage of participants with complete response (CR) and partial response (PR) based on independent radiographic review committee (IRRC) assessment. |
Approximately up to 24 months.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective response rate (ORR)
Délai: Approximately up to 24 months.
|
Percentage of participants with complete response (CR) and partial response (PR) based on investigator assessment. |
Approximately up to 24 months.
|
|
Duration of response (DOR)
Délai: Approximately up to 24 months.
|
Length of time response continued based on investigator and IRRC assessment. |
Approximately up to 24 months.
|
|
Progression-free survival (PFS)
Délai: Approximately up to 24 months.
|
The PFS is defined as the time from the date of enrollment to the date of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause, whichever occurred first. |
Approximately up to 24 months.
|
|
Overall survival (OS)
Délai: Approximately up to 24 months.
|
Time from the date of enrollment to the date of death for any cause. |
Approximately up to 24 months.
|
|
Cmax
Délai: Up to 21 days after the first dose.
|
Maximum serum concentration (Cmax) of HLX49, total antibody, and free payload. |
Up to 21 days after the first dose.
|
|
Tmax
Délai: Up to 21 days after the first dose.
|
Time to maximum serum concentration (Tmax) of HLX49, total antibody, and free payload. |
Up to 21 days after the first dose.
|
|
T1/2
Délai: Up to 21 days after the first dose.
|
Elimination half-life (t1/2) of HLX49, total antibody, and free payload. |
Up to 21 days after the first dose.
|
|
ADA (anti-drug antibody)
Délai: Approximately up to 24 months.
|
Positive rate of anti-HLX49 antibodies (ADA). |
Approximately up to 24 months.
|
|
NAb (neutralizing antibody)
Délai: Approximately up to 24 months.
|
Positive rate of neutralizing antibodies (NAb) against HLX49. |
Approximately up to 24 months.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HLX49-FIH101
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .